Top

Journal of Nanoparticle Research

Published in:

01-06-2023 | Review

A nanotherapeutic approach for fighting the odds against the malignant disorders

Authors: Samvedna Saini, Pranjal Dagar, Sakshi Gupta, Yatender Kumar

Published in: Journal of Nanoparticle Research | Issue 6/2023

Activate our intelligent search to find suitable subject content or patents.

search-config

AI-assisted search

Off

Abstract

Cancer, a combination of haematological and neoplastic malignancies, is a dreadful disease accounting for major fatalities worldwide. The domain of innovative nanoparticle-based technology has revolutionized the field of cancer therapeutics and imaging. With an emphasis on various nano-immunotherapeutic approaches, this study highlights the most recent developments in nano-immune engineering for metastatic tumours. Nanotechnology-based cancer immunotherapy has powered the (i) activation of T-cells in the tumour microenvironment (TME), (ii) preparation of efficient nanovaccines via nano-carriers and (iii) generation of smart nanomaterials which change their size/shape (size range of 1 to 1000 nm) and functionality upon activation in TME. The tumour microenvironment has an important, albeit contentious, role in controlling nanoparticle (NP) dispersion and subsequent biological consequences. The current study promotes the harnessing of potential peripheral immune cells by avoiding the creation of a pre-metastatic niche and, thus, suppressing tumour recurrence. This review descriptively accounts for a wide array of nanomaterials based on their polymeric constituents. Moreover, the current article explores the obstacles of integrating nanoscale immunomodulators and presents a forward-looking view of the novel nanotechnology-based approaches that may eventually prove helpful in eliminating metastatic illnesses.

previous article Assessment of gemcitabine hydrochloride-based nanotherapeutics in cancer: a proof of concept study

next article Fluorescent carbon nanomaterials from coal and its derivatives: structure, properties, and applications

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

inform now

“Cancer.” https://www.who.int/news-room/fact-sheets/detail/cancer (accessed Jun. 28, 2022)

Gong N, Sheppard NC, Billingsley MM, June CH, Mitchell MJ (2021) Nanomaterials for T-cell cancer immunotherapy. Nat Nanotechnol 16(1):25–36. https://doi.org/10.1038/S41565-020-00822-YCrossRef

O’Leary MC et al (2019) FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res 25(4):1142–1146. https://doi.org/10.1158/1078-0432.CCR-18-2035CrossRef

Bouchkouj N et al (2019) FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Clin Cancer Res 25(6):1702–1708. https://doi.org/10.1158/1078-0432.CCR-18-2743CrossRef

Guedan S, Ruella M, June CH (2019) Emerging cellular therapies for cancer. Annu Rev Immunol 37:145–171. https://doi.org/10.1146/annurev-immunol-042718-041407CrossRef

June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science 359(6382):1361–1365. https://doi.org/10.1126/science.aar6711CrossRef

Saini S, Kumar Y (2021) “Bispecific antibodies: a promising entrant in cancer immunotherapy,” Translational biotechnology: a journey from laboratory to clinics, pp 233–266. https://doi.org/10.1016/B978-0-12-821972-0.00014-9

Zhang P et al (2021) Nanotechnology-enhanced immunotherapy for metastatic cancer. The Innovation 2(4):100174. https://doi.org/10.1016/J.XINN.2021.100174CrossRef

Schuster M, Nechansky A, Loibner H, Kircheis R (2006) Cancer immunotherapy. Biotechnol J 1(2):138–147. https://doi.org/10.1002/BIOT.200500044CrossRef

10.

Kalos M et al (2011) T Cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73. https://doi.org/10.1126/SCITRANSLMED.3002842CrossRef

11.

Tang J, Shen D, Zhang J, Ligler FS, Cheng K (2015) Bispecific antibodies, nanoparticles and cells: bringing the right cells to get the job done. Expert Opin Biol Ther 15(9):1251. https://doi.org/10.1517/14712598.2015.1049944CrossRef

12.

Singh R, Sharma A, Saji J, Umapathi A, Kumar S, Daima HK (2022) Smart nanomaterials for cancer diagnosis and treatment. Nano Converg 9(1):1–39. https://doi.org/10.1186/S40580-022-00313-XCrossRef

13.

Wang Y, Zhang L, Guo S, Hatefi A, Huang L (2013) Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery. J Control Release 172(1):179–189. https://doi.org/10.1016/J.JCONREL.2013.08.015CrossRef

14.

Chang HI, Yeh MK (2012) Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomed 7:49. https://doi.org/10.2147/IJN.S26766CrossRef

15.

Navya PN, Kaphle A, Srinivas SP, Bhargava SK, Rotello VM, Daima HK (2019) Current trends and challenges in cancer management and therapy using designer nanomaterials. Nano Converg 6(1):1–30. https://doi.org/10.1186/S40580-019-0193-2CrossRef

16.

Nel AE et al (2009) Understanding biophysicochemical interactions at the nano–bio interface. Nat Mater 8(7):543–557. https://doi.org/10.1038/nmat2442CrossRef

17.

Smith DM, Simon JK, Baker JR (2013) Applications of nanotechnology for immunology. Nat Rev Immunol 13(8):592–605. https://doi.org/10.1038/nri3488CrossRef

18.

Irvine DJ, Hanson MC, Rakhra K, Tokatlian T (2015) Synthetic nanoparticles for vaccines and immunotherapY. Chem Rev 115(19):11109–11146. https://doi.org/10.1021/ACS.CHEMREV.5B00109/ASSET/IMAGES/ACS.CHEMREV.5B00109.SOCIAL.JPEG_V03CrossRef

19.

Bignold LP (2020) “Immunotherapies”. Principles of Tumors, pp 419–438. https://doi.org/10.1016/B978-0-12-816920-9.00016-X

20.

Shams F et al (2022) Nanotechnology-based products for cancer immunotherapy. Mol Biol Rep 49(2):1389–1412. https://doi.org/10.1007/S11033-021-06876-YCrossRef

21.

Nano-enabled immunomodulation (2021). Nat Nanotechnol 16:1. https://doi.org/10.1038/s41565-020-00842-8

22.

Yang M, Li J, Gu P, Fan X (2021) The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment. Bioact Mater 6(7):1973–1987. https://doi.org/10.1016/J.BIOACTMAT.2020.12.010CrossRef

23.

Balkwill FR, Capasso M, Hagemann T (2012) The tumor microenvironment at a glance. J Cell Sci 125(23):5591–5596. https://doi.org/10.1242/JCS.116392CrossRef

24.

Sushnitha M, Evangelopoulos M, Tasciotti E, Taraballi F (2020) Cell membrane-based biomimetic nanoparticles and the immune system: immunomodulatory interactions to therapeutic applications. Front Bioeng Biotechnol 8:627. https://doi.org/10.3389/FBIOE.2020.00627/BIBTEXCrossRef

25.

Blanco E, Shen H, Ferrari M (2015) Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 33:941–951. https://doi.org/10.1038/nbt.3330

26.

Wang L, Huo M, Chen Y, Shi J (2018) Tumor microenvironment-enabled nanotherapy. Adv Healthc Mater 7(8):1701156. https://doi.org/10.1002/ADHM.201701156CrossRef

27.

Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19(11):1423–1437. https://doi.org/10.1038/nm.3394

28.

Dang Y, Guan J (2020) Nanoparticle-based drug delivery systems for cancer therapy. Smart Mater Med 1:10–19. https://doi.org/10.1016/J.SMAIM.2020.04.001CrossRef

29.

Miao L, Huang L (2015) Exploring the tumor microenvironment with nanoparticles. Cancer Treat Res 166:193. https://doi.org/10.1007/978-3-319-16555-4_9CrossRef

30.

Ahmad F, Wang X, Li W (2019) Toxico-metabolomics of engineered nanomaterials: progress and challenges. Adv Funct Mater 29(51):1904268. https://doi.org/10.1002/ADFM.201904268CrossRef

31.

Westmeier D et al (2018) Nanoparticle binding attenuates the pathobiology of gastric cancer-associated Helicobacter pylori. Nanoscale 10(3):1453–1463. https://doi.org/10.1039/C7NR06573FCrossRef

32.

Cao L, Yuan J, Chen M, Shangguan W (2010) Photocatalytic energy storage ability of TiO2-WO3 composite prepared by wet-chemical technique. J Environ Sci 22(3):454–459. https://doi.org/10.1016/S1001-0742(09)60129-7CrossRef

33.

Armulik A, Genové G, Betsholtz C (2011) Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 21(2):193–215. https://doi.org/10.1016/J.DEVCEL.2011.07.001CrossRef

34.

Inoue S (1989) Ultrastructure of basement membranes. Int Rev Cytol 117(C):57–98. https://doi.org/10.1016/S0074-7696(08)61334-0CrossRef

35.

Yokoi K, Kojic M, Milosevic M, Tanei T, Ferrari M, Ziemys A (2014) Capillary-wall collagen as a biophysical marker of nanotherapeutic permeability into the tumor microenvironment. Cancer Res 74(16):4239–4246. https://doi.org/10.1158/0008-5472.CAN-13-3494/657846/AM/CAPILLARY-WALL-COLLAGEN-AS-A-BIOPHYSICAL-MARKER-OFCrossRef

36.

Singh M, Ma R, Zhu L (2021) Theoretical evaluation of enhanced gold nanoparticle delivery to PC3 tumors due to increased hydraulic conductivity or recovered lymphatic function after mild whole body hyperthermia. Med Biol Eng Comput 59(2):301–313. https://doi.org/10.1007/S11517-020-02308-4CrossRef

37.

Nikmaneshi MR, Firoozabadi B, Mozafari A, Munn LL (2020) A multi-scale model for determining the effects of pathophysiology and metabolic disorders on tumor growth. Sci Rep 10(1):1–20. https://doi.org/10.1038/s41598-020-59658-0CrossRef

38.

El-Kareh AW, Secomb TW 1995 “Effect of increasing vascular hydraulic conductivity on delivery of macromolecular drugs to tumor cells”. Int J Radiat Oncol*Biol*Phys 32(5):1419–1423. https://doi.org/10.1016/0360-3016(95)00110-K

39.

Kanapathipillai M, Brock A, Ingber DE (2014) Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment. Adv Drug Deliv Rev 79–80:107–118. https://doi.org/10.1016/J.ADDR.2014.05.005CrossRef

40.

Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM (2003) Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163(5):1801–1815. https://doi.org/10.1016/S0002-9440(10)63540-7CrossRef

41.

Yurchenco PD, Ruben GC (1987) Basement membrane structure in situ: evidence for lateral associations in the type IV collagen network. J Cell Biol 105(6):2559–2568. https://doi.org/10.1083/JCB.105.6.2559CrossRef

42.

Jain RK (1987) Transport of molecules in the tumor interstitium: a review. Cancer Res 47(12):3039–3051

43.

Puri A et al (2009) “Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic”, Critical Reviews&trade. Therapeutic Drug Carrier Systems 26(6):523–580. https://doi.org/10.1615/CRITREVTHERDRUGCARRIERSYST.V26.I6.10CrossRef

44.

Samir A, Elgamal BM, Gabr H, Sabaawy HE (2015) Nanotechnology applications in hematological malignancies (Review). Oncol Rep 34(3):1097. https://doi.org/10.3892/OR.2015.4100CrossRef

45.

Ferrara F, Schiffer CA (2013) Acute myeloid leukaemia in adults. The Lancet 381(9865):484–495. https://doi.org/10.1016/S0140-6736(12)61727-9CrossRef

46.

Zhuang J, Holay M, Park JH, Fang RH, Zhang J, Zhang L (2019) Nanoparticle delivery of immunostimulatory agents for cancer immunotherapy. Theranostics 9(25):7826–7848. https://doi.org/10.7150/THNO.37216CrossRef

47.

Dubensky TW, Reed SG (2010) Adjuvants for cancer vaccines. Semin Immunol 22(3):155–161. https://doi.org/10.1016/J.SMIM.2010.04.007CrossRef

48.

Apostólico Jde S, Lunardelli VA, Coirada FC, Boscardin SB, Rosa DS (2016) Adjuvants: classification, modus operandi, and licensing. J Immunol Res 2016:1459394. https://doi.org/10.1155/2016/1459394

49.

Smith TT et al (2017) In situ programming of leukaemia-specific T cells using synthetic DNA nano-carriers. Nat Nanotechnol 12(8):813–820. https://doi.org/10.1038/nnano.2017.57CrossRef

50.

García KP et al (2014) Zwitterionic-coated ‘stealth’ nanoparticles for biomedical applications: recent advances in countering biomolecular corona formation and uptake by the mononuclear phagocyte system. Small 10(13):2516–2529. https://doi.org/10.1002/SMLL.201303540CrossRef

51.

McMahon HT, Boucrot E (2011) Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol 12(8):517–533. https://doi.org/10.1038/nrm3151CrossRef

52.

Cevaal PM et al (2021) In vivo T cell-targeting nanoparticle drug delivery systems: considerations for rational design. ACS Nano 15(3):3736–3753. https://doi.org/10.1021/ACSNANO.0C09514/ASSET/IMAGES/MEDIUM/NN0C09514_0008.GIFCrossRef

53.

Selby LI, Cortez-Jugo CM, Such GK, Johnston APR (2017) Nanoescapology: progress toward understanding the endosomal escape of polymeric nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 9(5):e1452. https://doi.org/10.1002/WNAN.1452CrossRef

54.

Dai Q, Bertleff-Zieschang N, Braunger JA, Björnmalm M, Cortez-Jugo C, Caruso F (2018) Particle targeting in complex biological media. Adv Healthc Mater 7(1):1700575. https://doi.org/10.1002/ADHM.201700575CrossRef

55.

Schmid D et al (2017) “T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nat Commun 8(1):1–12. https://doi.org/10.1038/s41467-017-01830-8CrossRef

56.

Hao M, Chen B, Zhao X, Zhao N, Xu FJ (2020) Organic/inorganic nanocomposites for cancer immunotherapy. Mater Chem Front 4(9):2571–2609. https://doi.org/10.1039/D0QM00323ACrossRef

57.

Lee J, Chatterjee DK, Lee MH, Krishnan S (2014) Gold nanoparticles in breast cancer treatment: promise and potential pitfalls. Cancer Lett 347(1):46–53. https://doi.org/10.1016/J.CANLET.2014.02.006CrossRef

58.

Paul W, Sharma CP (2020) Inorganic nanoparticles for targeted drug delivery. Biointegration of Medical Implant Materials. https://doi.org/10.1016/B978-0-08-102680-9.00013-5

59.

Santos HA, Bimbo LM, Peltonen L, Hirvonen J (2015) Chapter 18: Inorganic Nanoparticles in Targeted Drug Delivery and Imaging (Book Chapter). In: Sanyog J, Devarajan P (eds) Targeted drug delivery – concepts and design (Advances in Delivery Science and Technology). Springer International Publishing, pp 571–613

60.

Bayda S et al (2017) Inorganic nanoparticles for cancer therapy: a transition from lab to clinic. Curr Med Chem 25(34):4269–4303. https://doi.org/10.2174/0929867325666171229141156CrossRef

61.

Lôbo GCNB, Paiva KLR, Silva ALG, Simões MM, Báo SN, Radicchi MA (2021) Nano-carriers used in drug delivery to enhance immune system in cancer therapy. Pharmaceutics 13(8):1167. https://doi.org/10.3390/PHARMACEUTICS13081167CrossRef

62.

Lim J, Yeap SP, Che HX, Low SC (2013) Characterization of magnetic nanoparticle by dynamic light scattering. Nanoscale Res Lett 8(1):1–14. https://doi.org/10.1186/1556-276X-8-381/FIGURES/10CrossRef

63.

Wang F et al (2018) Dextran coated Fe3O4 nanoparticles as a near-infrared laser-driven photothermal agent for efficient ablation of cancer cells in vitro and in vivo. Mater Sci Eng C 90:46–56. https://doi.org/10.1016/J.MSEC.2018.04.030CrossRef

64.

Singh A, Sahoo SK (2014) Magnetic nanoparticles: a novel platform for cancer theranostics. Drug Discov Today 19(4):474–481. https://doi.org/10.1016/J.DRUDIS.2013.10.005CrossRef

65.

Luk BT, Zhang L (2014) Current advances in polymer-based nanotheranostics for cancer treatment and diagnosis. ACS Appl Mater Interfaces 6(24):21859–21873. https://doi.org/10.1021/AM5036225/ASSET/IMAGES/LARGE/AM-2014-036225_0010.JPEGCrossRef

66.

Sun C, Lee JSH, Zhang M (2008) Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 60(11):1252–1265. https://doi.org/10.1016/J.ADDR.2008.03.018CrossRef

67.

Zanganeh S et al (2016) Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol 11(11):986–994. https://doi.org/10.1038/nnano.2016.168CrossRef

68.

Mukherjee S, Liang L, Veiseh O (2020) Recent advancements of magnetic nanomaterials in cancer therapy. Pharmaceutics 12(2):147. https://doi.org/10.3390/pharmaceutics12020147

69.

Dulińska-Litewka J, Łazarczyk A, Hałubiec P, Szafrański O, Karnas K, Karewicz A (2019) Superparamagnetic iron oxide nanoparticles-current and prospective medical applications. Materials (Basel) 12(4):617. https://doi.org/10.3390/ma12040617

70.

Montaseri H, Kruger CA, Abrahamse H (2021) Inorganic nanoparticles applied for active targeted photodynamic therapy of breast cancer. Pharmaceutics 13(3):296. https://doi.org/10.3390/PHARMACEUTICS13030296CrossRef

71.

Salunkhe AB, Khot VM, Pawar SH (2014) Magnetic hyperthermia with magnetic nanoparticles: a status review. Curr Top Med Chem 14(5):572–594. https://doi.org/10.2174/1568026614666140118203550CrossRef

72.

Ramishetti S et al (2015) Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles. ACS Nano 9(7):6706–6716. https://doi.org/10.1021/ACSNANO.5B02796CrossRef

73.

Zheng Y, Stephan MT, Gai SA, Abraham W, Shearer A, Irvine DJ (2013) In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. J Control Release 172(2):426–435. https://doi.org/10.1016/J.JCONREL.2013.05.037CrossRef

74.

Kim SS et al (2010) RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther 18(2):370–376. https://doi.org/10.1038/MT.2009.271CrossRef

75.

Ou W et al (2018) Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy. J Control Release 281:84–96. https://doi.org/10.1016/J.JCONREL.2018.05.018CrossRef

76.

Dunn ZS, Mac J, Wang P (2019) “T cell immunotherapy enhanced by designer biomaterials”. Biomaterials 217. https://doi.org/10.1016/J.BIOMATERIALS.2019.119265

77.

Lee CK, Atibalentja DF, Yao LE, Park J, Kuruvilla S, Felsher DW (2022) Anti-PD-L1 F(ab) conjugated PEG-PLGA nanoparticle enhances immune checkpoint therapy. Nanotheranostics 6(3):243. https://doi.org/10.7150/NTNO.65544CrossRef

78.

Ding Q et al (2015) Targeting and liposomal drug delivery to CD40L expressing T cells for treatment of autoimmune diseases. J Control Release 207:86–92. https://doi.org/10.1016/J.JCONREL.2015.03.035CrossRef

79.

Yang YSS et al (2018) Targeting small molecule drugs to T cells with antibody-directed cell-penetrating gold nanoparticles. Biomater Sci 7(1):113–124. https://doi.org/10.1039/C8BM01208CCrossRef

80.

Xie Y et al (2016) Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma. J Control Release 229:120–129. https://doi.org/10.1016/J.JCONREL.2016.03.029CrossRef

81.

Kandil R, Xie Y, Heermann R, Isert L, Jung K, Mehta A, Merkel OM (2019) Coming in and finding out: blending receptor-targeted delivery and efficient endosomal escape in a novel bio-responsive sirna delivery system for gene knockdown in Pulmonary T cells. Adv Ther (Weinh) 2(7):1900047. https://doi.org/10.1002/adtp.201900047

82.

Kosmides AK, Sidhom JW, Fraser A, Bessell CA, Schneck JP (2017) Dual targeting nanoparticle stimulates the immune system to inhibit tumor growth. ACS Nano 11(6):5417–5429. https://doi.org/10.1021/ACSNANO.6B08152/SUPPL_FILE/NN6B08152_SI_001.PDFCrossRef

83.

Soenen S, Rivera-Gil P, Montenegro J-M, Parak WJ, De Smedt S, Braeckmans K (2011) Cellular toxicity of inorganic nanoparticles: common aspects and guidelines for improved nanotoxicity evaluation. NANO TODAY 6(5):446–465. https://doi.org/10.1016/j.nantod.2011.08.001CrossRef

84.

Devi S et al (2022) Quantum dots: an emerging approach for cancer therapy. Front Mater 8:585. https://doi.org/10.3389/FMATS.2021.798440/BIBTEXCrossRef

85.

Chen L, Liang J (2020) An overview of functional nanoparticles as novel emerging antiviral therapeutic agents. Mater Sci Eng: C 112:110924. https://doi.org/10.1016/J.MSEC.2020.110924CrossRef

86.

Wen L et al (2014) Labeling the nucleocapsid of enveloped baculovirus with quantum dots for single-virus tracking. Biomaterials 35(7):2295–2301. https://doi.org/10.1016/J.BIOMATERIALS.2013.11.069CrossRef

87.

S. Tope, S. Saudagar, N. Kale, S. Khambayat, and K. Bhise, “Review: therapeutic application of quantum dots (QD),” THE PHARMA INNOVATION-JOURNAL, vol. 2, no. 12, 2014, Accessed: Jun. 28, 2022. [Online]. Available: www.thepharmajournal.com

88.

Tang L et al (2022) Multifunctional inorganic nanomaterials for cancer photoimmunotherapy. Cancer Commun 42(2):141–163. https://doi.org/10.1002/CAC2.12255CrossRef

89.

Song G et al (2019) Toxicity of functionalized multi-walled carbon nanotubes on bone mesenchymal stem cell in rats. Dent Mater J 38(1):127–135. https://doi.org/10.4012/DMJ.2017-313CrossRef

90.

Hesp NCH et al (2021) “Nano-imaging photoresponse in a moiré unit cell of minimally twisted bilayer graphene”. Nat Commun 12(1). https://doi.org/10.1038/S41467-021-21862-5

91.

Sharma H, Mondal S (2020) Functionalized graphene oxide for chemotherapeutic drug delivery and cancer treatment: a promising material in nanomedicine. Int J Mol Sci 21(17):6280. https://doi.org/10.3390/IJMS21176280CrossRef

92.

Zheng Y et al (2021) “2D nanomaterials for tissue engineering and regenerative nanomedicines: recent advances and future challenges”. Adv Healthc Mater 10(7). https://doi.org/10.1002/ADHM.202001743.

93.

Karimi Shervedani R, Samiei Foroushani M, Kefayat A, Torabi M, Rahnemaye Rahsepar F (2018) Construction and characterization of a theranostic system based on graphene/manganese chelate. Biosens Bioelectron. 117:794–801. https://doi.org/10.1016/J.BIOS.2018.07.011CrossRef

94.

Choi Y et al (2020) Graphene oxide nanoribbon hydrogel: viscoelastic behavior and use as a molecular separation membrane. ACS Nano 14(9):12195–12202. https://doi.org/10.1021/ACSNANO.0C05902CrossRef

95.

Eskandari P, Abousalman-Rezvani Z, Roghani-Mamaqani H, Salami-Kalajahi M (2021) “Polymer-functionalization of carbon nanotube by in situ conventional and controlled radical polymerizations,. Adv Colloid Interface Sci 294:102471. https://doi.org/10.1016/J.CIS.2021.102471

96.

Yang Z, Ma Y, Zhao H, Yuan Y, Kim BYS (2020) Nanotechnology platforms for cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 12(2):e1590. https://doi.org/10.1002/WNAN.1590CrossRef

97.

Hess KL, Medintz IL, Jewell CM (2019) Designing inorganic nanomaterials for vaccines and immunotherapies. Nano Today 27:73–98. https://doi.org/10.1016/J.NANTOD.2019.04.005CrossRef

98.

Sharma A, Goyal AK, Rath G (2018) Recent advances in metal nanoparticles in cancer therapy. J Drug Target 26(8):617–632. https://doi.org/10.1080/1061186X.2017.1400553CrossRef

99.

Shariatzadeh S et al (2022) Metallic nanoparticles for the modulation of tumor microenvironment; a new horizon. Front Bioeng Biotechnol 10:219. https://doi.org/10.3389/FBIOE.2022.847433/BIBTEXCrossRef

100.

Evans ER, Bugga P, Asthana V, Drezek R (2018) Metallic nanoparticles for cancer immunotherapy. Mater Today (Kidlington) 21(6):673. https://doi.org/10.1016/J.MATTOD.2017.11.022CrossRef

101.

Sperling RA, Parak WJ (2010) Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles. Philos Trans A Math Phys Eng Sci 368(1915):1333–1383. https://doi.org/10.1098/RSTA.2009.0273CrossRef

102.

Salatin S, Maleki Dizaj S, Yari Khosroushahi A (2015) Effect of the surface modification, size, and shape on cellular uptake of nanoparticles. Cell Biol Int 39(8):881–90. https://doi.org/10.1002/cbin.10459CrossRef

103.

Niikura K, Matsunaga T, Suzuki T, Kobayashi S, Yamaguchi H, Orba Y, Kawaguchi A, Hasegawa H, Kajino K, Ninomiya T, Ijiro K, Sawa H (2013) Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo. ACS Nano 7(5):3926–3938. https://doi.org/10.1021/nn3057005CrossRef

104.

Kennedy LC et al (2011) T cells enhance gold nanoparticle delivery to tumors in vivo. Nanoscale Res Lett 6(1):283. https://doi.org/10.1186/1556-276X-6-283CrossRef

105.

Karlsson J, Vaughan HJ, Green JJ (2018) Biodegradable polymeric nanoparticles for therapeutic cancer treatments. Annu Rev Chem Biomol Eng 9:105–127. https://doi.org/10.1146/annurev-chembioeng-060817-084055

106.

Gagliardi A, Giuliano E, Venkateswararao E, Fresta M, Bulotta S, Awasthi V, Cosco D (2021) Biodegradable polymeric nanoparticles for drug delivery to solid tumors. Front Pharmacol 12:17. https://doi.org/10.3389/FPHAR.2021.601626/BIBTEXCrossRef

107.

Li B, Li Q, Mo J, Dai H (2017) Drug-loaded polymeric nanoparticles for cancer stem cell targeting. Front Pharmacol 8(1):51. https://doi.org/10.3389/FPHAR.2017.00051/BIBTEXCrossRef

108.

Ahuja R, Panwar N, Meena J, Singh M, Sarkar DP, Panda AK (2020) Natural products and polymeric nano-carriers for cancer treatment: a review. Environ Chem Lett 18(6):2021–2030. https://doi.org/10.1007/S10311-020-01056-Z/TABLES/4CrossRef

109.

Anju S, Prajitha N, Sukanya VS, Mohanan PV (2020) Complicity of degradable polymers in health-care applications. Mater Today Chem 16:100236. https://doi.org/10.1016/J.MTCHEM.2019.100236CrossRef

110.

Su S, Kang PM (2020) Systemic review of biodegradable nanomaterials in nanomedicine. Nanomaterials 10(656):656. https://doi.org/10.3390/NANO10040656CrossRef

111.

Avramović N, Mandić B, Savić-Radojević A, Simić T (2020) “Polymeric nano-carriers of drug delivery systems in cancer therapy”. Pharmaceutics 12(4). https://doi.org/10.3390/PHARMACEUTICS12040298

112.

Gagliardi M (2017) Biomimetic and bioinspired nanoparticles for targeted drug delivery. Ther Deliv 8(5):289–299. https://doi.org/10.4155/tde-2017-0013

113.

Cisneros CG, Bloemen V, Mignon A (2021) Synthetic, natural, and semisynthetic polymer carriers for controlled nitric oxide release in dermal applications: a review. Polymers (Basel) 13(5):1–26. https://doi.org/10.3390/POLYM13050760CrossRef

114.

Sithole MN, Choonara YE, du Toit LC, Kumar P, Pillay V (2017) A review of semi-synthetic biopolymer complexes: modified polysaccharide nano-carriers for enhancement of oral drug bioavailability. Pharm Dev Technol 22(2):283–295. https://doi.org/10.1080/10837450.2016.1212882

115.

Rahman M, Hasan MR (2019) “Synthetic biopolymers” 1–43. https://doi.org/10.1007/978-3-319-95990-0_1

116.

Akbarzadeh A et al (2013) Liposome: classification, preparation, and applications. Nanoscale Res Lett 8(1):102. https://doi.org/10.1186/1556-276X-8-102CrossRef

117.

Kulkarni JA, Cullis PR, Van Der Meel R (2018) Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther 28(3):146–157. https://doi.org/10.1089/NAT.2018.0721CrossRef

118.

Shrestha H, Bala R, Arora S (2014) Lipid-based drug delivery systems. J Pharm (Cairo) 2014:1–10. https://doi.org/10.1155/2014/801820CrossRef

119.

Mehanna MM, Mneimneh AT (2021) Formulation and applications of lipid-based nanovehicles: spotlight on self-emulsifying systemS. Adv Pharm Bull 11(1):56–67. https://doi.org/10.34172/apb.2021.006CrossRef

120.

Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S (2015) “Advances and challenges of liposome assisted drug delivery”. Front Pharmacol 6:(DEC).https://doi.org/10.3389/FPHAR.2015.00286.

121.

Mahmoud K, Swidan S, El-Nabarawi M, Teaima M (2022) Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances. J Nanobiotechnol 20(1):1–42. https://doi.org/10.1186/S12951-022-01309-9CrossRef

122.

Hua S, Wu SY (2013) “The use of lipid-based nano-carriers for targeted pain therapies”. Front Pharmacol 4. https://doi.org/10.3389/FPHAR.2013.00143.

123.

Naseri N, Valizadeh H, Zakeri-Milani P (2015) Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull 5(3):305–313. https://doi.org/10.15171/APB.2015.043CrossRef

124.

B. García-Pinel et al (2019) “Lipid-based nanoparticles: application and recent advances in cancer treatment”. Nanomaterials 9(4). https://doi.org/10.3390/NANO9040638

125.

Le MQ, Carpentier R, Lantier I, Ducournau C, Dimier-Poisson I, Betbeder D (2018) Residence time and uptake of porous and cationic maltodextrin-based nanoparticles in the nasal mucosa: Comparison with anionic and cationic nanoparticles. Int J Pharm 550(1–2):316–324. https://doi.org/10.1016/j.ijpharm.2018.08.054

126.

Rasmussen MK, Pedersen JN, Marie R (2020) Size and surface charge characterization of nanoparticles with a salt gradient. Nat Commun 11(1):1–8. https://doi.org/10.1038/s41467-020-15889-3CrossRef

127.

Chauhan I, Yasir M, Verma M, Singh AP (2020) Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery. Adv Pharm Bull 10(2):150–165. https://doi.org/10.34172/apb.2020.021CrossRef

128.

Dhiman N, Awasthi R, Sharma B, Kharkwal H, Kulkarni GT (2021) Lipid nanoparticles as carriers for bioactive delivery. Front Chem 9:268. https://doi.org/10.3389/FCHEM.2021.580118/BIBTEXCrossRef

129.

M. Üner, “Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems,” Pharmazie, vol. 61, no. 5, pp. 375–386, May 2006, Accessed: Jun. 30, 2022. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/16724531/

130.

Zhang Y, Lin S, Wang XY, Zhu G (2019) Nanovaccines for cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 11(5):e1559. https://doi.org/10.1002/WNAN.1559CrossRef

131.

Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480(7378):480–489. https://doi.org/10.1038/nature10673CrossRef

132.

Fioretti D, Iurescia S, Fazio VM, Rinaldi M (2010) “DNA vaccines: developing new strategies against cancer”. J Biomed Biotechnol 2010. https://doi.org/10.1155/2010/174378

133.

Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML (2002) Vaccination against the HER-2/neu oncogenic protein. Endocrine-Related Cancer Endocr Relat Cancer Endocr. Relat Cancer 9(1):33–44. https://erc.bioscientifica.com/view/journals/erc/9/1/11914181.xml

134.

Faghfuri E, Pourfarzi F, Faghfouri AH, Abdoli Shadbad M, Hajiasgharzadeh K, Baradaran B (2021) Recent developments of RNA-based vaccines in cancer immunotherapy. Expert Opin Biol Ther 21(2):201–218. https://doi.org/10.1080/14712598.2020.1815704

135.

Peng M et al (2019) Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer 18(1):1–14. https://doi.org/10.1186/S12943-019-1055-6CrossRef

136.

Zhang Z et al (2021) Neoantigen: a new breakthrough in tumor immunotherapy. Front Immunol 12:1297. https://doi.org/10.3389/FIMMU.2021.672356/BIBTEXCrossRef

137.

Keskin DB et al (2018) Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565(7738):234–239. https://doi.org/10.1038/s41586-018-0792-9CrossRef

138.

Hu HG, Li YM (2020) Emerging adjuvants for cancer immunotherapy. Front Chem 8:601. https://doi.org/10.3389/FCHEM.2020.00601/BIBTEXCrossRef

139.

Temizoz B, Kuroda E, Ishii KJ (2016) Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol 28(7):329–338. https://doi.org/10.1093/INTIMM/DXW015CrossRef

140.

Montomoli E, Piccirella S, Khadang B, Mennitto E, Camerini R, De Rosa A (2014) “Current adjuvants and new perspectives in vaccine formulation”. 10(7):1053–1061. https://doi.org/10.1586/ERV.11.48.

141.

Banday AH, Jeelani S, Hruby VJ (2014) “Cancer vaccine adjuvants – recent clinical progress and future perspectives”. 37(1):1–11. https://doi.org/10.3109/08923973.2014.971963

142.

Ni Q et al (2020) A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer. Sci Adv 6(12):6071–6089. https://doi.org/10.1126/SCIADV.AAW6071/SUPPL_FILE/AAW6071_SM.PDFCrossRef

143.

Aikins ME, Xu C, Moon JJ (2020) Engineered nanoparticles for cancer vaccination and immunotherapy. Acc Chem Res 53(10):2094–2105. https://doi.org/10.1021/ACS.ACCOUNTS.0C00456/ASSET/IMAGES/MEDIUM/AR0C00456_0007.GIFCrossRef

144.

Kenchegowda M et al (2021) Smart nano-carriers as an emerging platform for cancer therapy: a review. Molecules 27(1):146. https://doi.org/10.3390/MOLECULES27010146CrossRef

145.

Pérez-Herrero E, Fernández-Medarde A (2015) Advanced targeted therapies in cancer: drug nano-carriers, the future of chemotherapy. Eur J Pharm Biopharm 93:52–79. https://doi.org/10.1016/J.EJPB.2015.03.018CrossRef

146.

Tang L, Li J, Zhao Q, Pan T, Zhong H, Wang W (2021) Advanced and innovative nano-systems for anticancer targeted drug delivery. Pharmaceutics 13(8):1151. https://doi.org/10.3390/PHARMACEUTICS13081151CrossRef

147.

Xia Q, Zhang Y, Li Z, Hou X, Feng N (2019) Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application. Acta Pharm Sin B 9(4):675–689. https://doi.org/10.1016/J.APSB.2019.01.011CrossRef

148.

Rossi L et al (2016) Engineering erythrocytes for the modulation of drugs’ and contrasting agents’ pharmacokinetics and biodistribution. Adv Drug Deliv Rev 106:73–87. https://doi.org/10.1016/J.ADDR.2016.05.008CrossRef

149.

Han X, Wang C, Liu Z (2018) Red blood cells as Smart Delivery Systems. Bioconjug Chem 29(4):852–860. https://doi.org/10.1021/ACS.BIOCONJCHEM.7B00758/ASSET/IMAGES/MEDIUM/BC-2017-00758Z_0006.GIFCrossRef

150.

Persano S, Das P, Pellegrino T (2021) Magnetic nanostructures as emerging therapeutic tools to boost anti-tumour immunity. Cancers 13(11):2735. https://doi.org/10.3390/CANCERS13112735CrossRef

151.

Rivera-Rodriguez A et al (2021) Tracking adoptive t cell immunotherapy using magnetic particle imaging. Nanotheranostics 5(4):431–444. https://doi.org/10.7150/NTNO.55165CrossRef

152.

Hussein-Al-Ali SH, Hussein MZ, Bullo S, Arulselvan P (2021) Chlorambucil-iron oxide nanoparticles as a drug delivery system for leukemia cancer cells. Int J Nanomed 16:6205–6216. https://doi.org/10.2147/IJN.S312752CrossRef

153.

Li N, Peng LH, Chen X, Nakagawa S, Gao JQ (2011) Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers. Vaccine 29(37):6179–6190. https://doi.org/10.1016/J.VACCINE.2011.06.086CrossRef

154.

Wakabayashi R, Sakuragi M, Kozaka S, Tahara Y, Kamiya N, Goto M (2018) Solid-in-oil peptide nano-carriers for transcutaneous cancer vaccine delivery against melanoma. Mol Pharm 15(3):955–961. https://doi.org/10.1021/ACS.MOLPHARMACEUT.7B00894/SUPPL_FILE/MP7B00894_SI_001.PDFCrossRef

155.

Kitaoka M, Wakabayashi R, Kamiya N, Goto M (2016) Solid-in-oil nanodispersions for transdermal drug delivery systems. Biotechnol J 11(11):1375–1385. https://doi.org/10.1002/BIOT.201600081CrossRef

156.

Ahmad F, Abubshait SA, Abubshait HA (2020) Untargeted metabolomics for Achilles heel of engineered nanomaterials’ risk assessment. Chemosphere 262:128058–128058. https://doi.org/10.1016/J.CHEMOSPHERE.2020.128058CrossRef

157.

Kawai S, Niwano M, Sato M (2019) A risk assessment framework for self-management of poorly soluble low toxic nanomaterials. Heliyon 5(8):e02165. https://doi.org/10.1016/J.HELIYON.2019.E02165CrossRef

158.

Pettitt ME, Lead JR (2013) Minimum physicochemical characterisation requirements for nanomaterial regulation. Environ Int 52:41–50. https://doi.org/10.1016/J.ENVINT.2012.11.009CrossRef

159.

Nicoletta FP, Iemma F (2023) Nanomaterials for drug delivery and cancer therapy. Nanomaterials 13(1):207. https://doi.org/10.3390/nano13010207

160.

Zhang D, Ma XL, Gu Y, Huang H, Zhang GW (2020) Green synthesis of metallic nanoparticles and their potential applications to treat cancer. Front Chem 8:799. https://doi.org/10.3389/FCHEM.2020.00799/BIBTEXCrossRef

161.

Gill P (2013) Nano-carriers, nanovaccines, and nanobacteria as nanobiotechnological concerns in modern vaccines. Scientia Iranica 20(3):1003–1013. https://doi.org/10.1016/J.SCIENT.2013.05.012CrossRef

162.

Swami A et al (2014) Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci U S A 111(28):10287–10292. https://doi.org/10.1073/PNAS.1401337111/SUPPL_FILE/PNAS.201401337SI.PDFCrossRef

163.

Chen F et al (2018) Synthesis of CuInZnS quantum dots for cell labelling applications. Ceram Int 44:S34–S37. https://doi.org/10.1016/J.CERAMINT.2018.08.276CrossRef

164.

Wu F, Yuan H, Zhou C, Mao M, Liu Q, Shen H, Cen Y, Qin Z, Ma L, Song Li L (2016) Multiplexed detection of influenza A virus subtype H5 and H9 via quantum dot-based immunoassay. Biosens Bioelectron 77:464–470. https://doi.org/10.1016/j.bios.2015.10.002CrossRef

Title: A nanotherapeutic approach for fighting the odds against the malignant disorders
Authors: Samvedna Saini
Pranjal Dagar
Sakshi Gupta
Yatender Kumar
Publication date: 01-06-2023
Publisher: Springer Netherlands
Published in: Journal of Nanoparticle Research / Issue 6/2023
Print ISSN: 1388-0764
Electronic ISSN: 1572-896X
DOI: https://doi.org/10.1007/s11051-023-05754-x

Springer Professional

Abstract

Please log in to get access to your license.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Springer Professional "Technik"

Other articles of this Issue 6/2023

Dopamine-modified nanospheres of oxalic-bimetal for T1/T2 dual-modal MRI and photothermal tumour treatment

DNA:TiO2 nanoparticle nanoassemblies: effect of temperature and nanoparticle concentration on aggregation

Fluorescent carbon nanomaterials from coal and its derivatives: structure, properties, and applications

Spatial graph structure estimation of nanoparticles using centroid-to-contour distance analysis and deep encoder framework

Flash nanoprecipitation of hafnia nanoparticle computed tomography contrast agent

In situ electron microscopy techniques for nanoparticle dispersion analysis of commercial sunscreen

Premium Partners